Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients by Amalia Azzariti, Simona De Summa, Tommaso M. Marvulli, Ivana De Risi, Giuseppe De Palma, Roberta Di Fonte, Rossella Fasano, Simona Serratì, Sabino Strippoli, Letizia Porcelli, Michele Guida

Subjects: Get full text

Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma by Marek Pasek, Eva Sticová, Emanuel Marques, Vojtěch Tretera, Petr Arenberger, Monika Arenbergerová

Subjects: “…melanoma, anti-PD-1, anti-LAG-3, adverse events…”
Get full text

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies by Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, Chencheng Han, Rui Liu, Chen Hu, Qingyu Wang, Jun Zhu, Yongqiang Shan

Subjects: “…Anti-PD-1/PD-L1…”
Get full text

Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer by Yuanyuan Wang, Chenxi Hu, Tianpeng Du, Jiawen Li, Kaiyuan Hui, Xiaodong Jiang

Subjects: “…anti-PD-1…”
Get full text

Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab by Efterpi Zafiriou, Emmanouil Karampinis, Vasileios Papadopoulos, Georgia Stefani, Athanasios Kotsakis, George Vassilopoulos

Subjects: Get full text

Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening by Dan Zhao, Ravindra Deshpande, Kerui Wu, Abhishek Tyagi, Sambad Sharma, Shih-Ying Wu, Fei Xing, Stacey O'Neill, Jimmy Ruiz, Feng Lyu, Kounosuke Watabe

Subjects: Get full text

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer by Shuailei Dong, Chen Wei, Xueting Wang, Xinyi Yang, Wei Shen, Shuyi Li, Jiye Xu, Yijie Ma, Liangyu Bie, Wenyue Yu, Ning Li

Subjects: Get full text

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1... by Toshio Shimizu, Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Talia Golan, Anthony Tolcher

Subjects: Get full text

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budi... by Toshio Shimizu, Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Talia Golan, Anthony Tolcher

Subjects: Get full text

Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review by Beata Mayer, Pavel Babál, Lucia Krivošíková

Subjects: Get full text

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model by Ismail M Meraz, Mourad Majidi, Renduo Song, Feng Meng, Lihui Gao, Qi Wang, Jing Wang, Elizabeth J Shpall, Jack A Roth

Subjects: Get full text

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study by Ping Zhou, Bing Liu, Ning Shen, Xiaoting Fan, Shangwei Lu, Zhijuan Kong, Ying Gao, Zhimei Lv, Rong Wang

Subjects: Get full text